Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02449239 · ClinicalTrials.gov registry record · Phase 3
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
A Phase 3 study of Bladder Cancer, sponsored by Sesen Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 133
- Enrollment target
- 20
- Study locations
NCT02449239 is a Phase 3 study of Bladder Cancer that has completed, run by Sesen Bio. The registered enrollment target is 133 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT02449239, a Phase 3 study of Bladder Cancer, has completed, sponsored by Sesen Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 133 participants
- Enrollment target
- 20
- Study locations
Study Summary
Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy. Vicinium is an experimental agent that may provide an alternative to cystectomy
Conditions Studied
Interventions
- BIOLOGICAL Vicinium
Study Locations (20)
California
- - Los Angeles
- - Los Angeles
- - Los Angeles
- - Los Angeles
- - Redwood City
- - San Bernardino
- - Sherman Oaks
- - Torrance
Florida
- - Bradenton
- - Daytona Beach
- - Orlando
- - St. Petersburg
- - Tampa
- - Wellington
Arizona
- - Phoenix
- - Tucson
Alabama
- - Birmingham
Arkansas
- - Little Rock
Colorado
- - Englewood
District of Columbia
- - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2015-08 |
| Est. Completion | 2022-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02449239
The ClinicalTrials.gov registry entry for NCT02449239 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Sesen Bio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Vicinium is the first listed.
NCT02449239 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02449239 about?
NCT02449239 is a clinical study titled "Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG". Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy. Vicinium is an experimental agent that may provide an alternative to cystectomy
What is the current status of trial NCT02449239?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 133 participants. The study started on 2015-08. Estimated completion is 2022-05.
What conditions does trial NCT02449239 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT02449239?
The interventions under investigation include: Vicinium (BIOLOGICAL).
Who is sponsoring clinical trial NCT02449239?
This trial is sponsored by Sesen Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02449239 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
RECRUITING · Phase 3
-
A Study of Surgical Techniques During Cystectomy
RECRUITING · Phase 3
-
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
RECRUITING · Phase 3
-
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.